# Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers

> **NCT02432664** · PHASE1 · TERMINATED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 85 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ODM-108 Part I
- **DRUG:** Placebo Part I
- **DRUG:** ODM-108-Part II
- **DRUG:** Placebo Part II
- **DRUG:** ODM-108 Part III
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT02432664
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-14
- **Primary completion:** 2016-04-22
- **Final completion:** 2016-04-22
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** The study was terminated after the second cohort had completed Part II due complex PK results. There were no safety concerns.
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432664, "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02432664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*